Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/23/2025

First-Line Treatment for Clostridioides difficile Infection

Treatment Recommendations

  • The American College of Physicians recommends metronidazole as the first-line antibiotic for non-severe, first episode CDI, while vancomycin is recommended for first episode CDI of any disease severity 1, 2, 3
  • For non-severe CDI, metronidazole 500 mg orally three times daily for 10-14 days is recommended, supported by high-quality evidence showing similar mortality outcomes between metronidazole and vancomycin in non-severe cases 1, 4, 5
  • For severe CDI, vancomycin 125 mg orally four times daily for 10-14 days is recommended, with patients having lower all-cause 30-day mortality compared to those treated with metronidazole 1, 3, 4
  • The Infectious Diseases Society of America (IDSA) recommends fidaxomicin as one of the first-line treatment regimens, with similar clinical cure rates to vancomycin but lower recurrence rates 1, 3

Disease Severity Criteria

  • Non-severe CDI is characterized by diarrhea without features of severe or fulminant CDI 7
  • Severe CDI is characterized by temperature >38.5°C, white blood cell count >15,000 cells/mL, serum creatinine >1.5 mg/dL, albumin <2.5 mg/dL, or 10 or more bowel movements within 24 hours 7
  • Fulminant CDI is characterized by hypotension, shock, end-organ failure, ileus, toxic megacolon, or colonic perforation 1, 3, 6, 7

Treatment of Recurrent CDI

  • For first recurrence, oral vancomycin 125 mg four times daily for 10 days is recommended, especially if metronidazole was used for the first episode 3, 4
  • For second or subsequent recurrences, vancomycin in tapered and pulsed regimens or fidaxomicin is recommended, with fecal microbiota transplantation (FMT) considered for multiple recurrences or refractory cases 4, 6

Important Considerations

  • Discontinuing the inciting antibiotic therapy is recommended if possible, and "test of cure" should not be performed after CDI treatment 4, 5
  • Vancomycin may increase the risk of vancomycin-resistant Enterococci (VRE) acquisition, and prolonged use of metronidazole may be associated with neurotoxicity 1, 2, 3